|
Hutchmed China Ltd on Thursday reported lower revenue for 2025, but reported sharply higher profit following a major divestment gain and said it expects oncology revenue growth in 2026. The Hong Kong-based biopharmaceutical firm posted total revenue of $548.5 million for 2025, down 13% from $630.2 million in 2024. Oncology and immunology consolidated revenue fell 21% to $285.5 million from $363.4 million. In-market sales of Fruzaqla, its colon cancer medicine, rose 26% to $366.2 million from $290.6 million, while Elunate sales declined 13% to $100.1 million from $115.0 million. Sales of Sulanda for pancreatic tumours fell 45% to $27.0 million from $49.0 million. Operating expenses narrowed to $587.7 million from $673.9 million, reflecting lower research and development and selling and administrative costs. Net income attributable to Hutchmed surged to $456.9 million from $37.7 million, boosted by a $415.8 million gain net of tax on the divestment of a 45% stake in its Shanghai Hutchison Pharmaceuticals joint venture. Basic earnings per share increased to $0.53 from $0.04. Cash, cash equivalents and short-term investments stood at $1.37 billion at year-end, up from $836.1 million a year earlier. Looking ahead, Hutchmed guided for 2026 oncology and immunology consolidated revenue in the range of $330 million to $450 million, citing continued growth in China commercial operations, further global expansion of Fruzaqla and potential new partnership opportunities. Chair Dan Eldar said: ‘Our company is at a pivotal point. We have repositioned our commercial team to better meet challenges in our environment and to spur sales growth in China, delivering significant improvements from the second quarter of 2025. With late-stage programs, we have demonstrated impressive clinical results in phase III trials leading to NDA filings, and we have proven experience in gaining approval with major regulatory authorities.’ Hutchmed China shares were down 1.7% at 202.57 pence in London on Thursday morning. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
